PTX-35 

PTX-35 is a costimulatory agonist antibody targeting TNFRSF25 as well as an immune activator that selectively regulates activated CD8⁺ T cells. PTX-35 enhances the expansion, survival and effector functions of T cells, while reducing the inhibitory activity of regulatory T cells and impairing their stability. PTX-35 exhibits anti-tumor activity, effectively delaying tumor progression and prolonging survival. PTX-35 has a synergistic effect with anti-OX40 agonist antibodies. PTX-35 can be widely used in research on related diseases such as colon cancer and melanoma^[1][2].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

TNFRSF25

Mouse PTX-35 (mPTX-35) , in the presence of tumor antigens, reprograms the Treg cell phenotype by reducing Treg suppressive activity and increasing Treg plasticity toward inflammatory Th1 and Th17 cells, which is associated with delayed tumor progression in a murine melanoma model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

8718  [NCBI]

Q93038

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.58 kDa

Liquid

Colorless to light yellow

[3H][P][F,Cl,Br,I]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized Human-DR3-his can bind PTX-35. The EC₅₀ for this effect is 69.63 ng/mL.

• [1]. Tahiliani V, et al. Abstract 2224A: A novel TNFRSF25 agonist, PTX35, synergizes with Gp96-Ig/OX40L-Ig to enhance effector and memory anti-tumor CD8+ T cell responses and delay tumor growth[J]. Cancer Research, 2020, 80(16_Supplement): 2224A-2224A.

  [2]. Kalim K W, et al. PTX-35, a potential first-in-class TNFRSF25 agonist, reduced the suppressive activity of regulatory T cells and enhanced CD4+ T cell effector responses, in the presence of tumor antigens, in a murine melanoma model[J]. Cancer Research, 2021, 81(13_Supplement): 604-604.

  [3]. Simons F E R. Advances in H1-antihistamines[J]. New England Journal of Medicine, 2004, 351(21): 2203-2217.